ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity

Annals of the New York Academy of Sciences

Volumn 1029, Issue , 2004, Pages 193-208

  Lycke, Nils ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Adjuvant; ADP ribosylation; Cholera toxin; CTA1 DD; IgA; Mucosal; Tolerance

Indexed keywords

B7 ANTIGEN; BACTERIAL ENZYME; CD4 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CHOLERA TOXIN; CHOLERA TOXIN B SUBUNIT; CTA1 DD ADJUVANT; CTA1R7K DD ADJUVANT; HLA B7 ANTIGEN; HLA B7RP 1 ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN A; IMMUNOLOGICAL ADJUVANT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ADOPTIVE TRANSFER; ANTIGEN BINDING; ANTIGEN DELIVERY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; CELL MATURATION; CONFERENCE PAPER; CONJUGATE; DENDRITIC CELL; ENZYME ACTIVITY; GERMINAL CENTER; IMMUNITY; IMMUNOLOGICAL PRIMING; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VIVO STUDY; LYMPH FOLLICLE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE MIGRATION; MUCOSAL IMMUNITY; NONHUMAN; PROTEIN TARGETING; SPLEEN; T LYMPHOCYTE SUBPOPULATION; TRANSGENICS;

EID: 14544271339     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1309.036     Document Type: Conference Paper

References (72)

1. GARDBY, E. et al. 2003. Strong differential regulation of serum and mucosal IgA responses as revealed in CD28-deficient mice using cholera toxin adjuvant. J. Immunol. 170: 55-63.
2. GARDBY, E., P. LANE & N.Y. LYCKE. 1998. Requirements for B7-CD28 costimulation in mucosal IgA responses: paradoxes observed in CTLA4-H gamma 1 transgenic mice. J. Immunol. 161: 49-59.
3. SMITH, K.M. et al. 2003. Inducible costimulatory molecule-B7-related protein 1 interactions are important for the clonal expansion and B cell helper functions of naive, Th1, and Th2 T cells. J. Immunol. 170: 2310-2315.
4. SMITH, K.M., F. MCASKILL & P. GARSIDE. 2002. Orally tolerized T cells are only able to enter B cell follicles following challenge with antigen in adjuvant, but they remain unable to provide B cell help. J. Immunol. 168: 4318-4325.
5. MATZINGER, P. & S. GUERDER. 1989. Does T-cell tolerance require a dedicated antigen-presenting cell? Nature 338: 74-76.
6. UNDERHILL, D.M. & A. OZINSKY. 2002. Toll-like receptors: key mediators of microbe detection. Curr. Opin. Immunol. 14: 103-110.
7. BARTON, G.M. & R. MEDZHITOV. 2002. Control of adaptive immune responses by Toll-like receptors. Curr. Opin. Immunol. 14: 380-383.
8. RICCIARDI-CASTAGNOLI, P. & F. GRANUCCI. 2002. Opinion: Interpretation of the complexity of innate immune responses by functional genomics. Nat. Rev. Immunol. 2: 881-889.
9. SHARPE, A. 1995. Analysis of costimulation in vivo using transgenic and knockout mice. Curr. Opin. Immunol. 7: 389-395.
10. EDELMAN, R. 1997. Adjuvants for the future. In New Generation Vaccines. G.C. Woodrow et al., Eds.: 173-192. Marcel Dekker, Inc. New York.
11. VOGEL, F.R. 1995. Immunologic adjuvants for modern vaccine formulations. Ann. N.Y. Acad. Sci. 754: 153-160.
12. LEVINE, M.M. 2003. Can needle-free administration of vaccines become the norm in global immunization? Nat. Med. 9: 99-103.
13. LEVINE, M.M. & G. DOUGAN. 1998. Optimism over vaccines administered via mucosal surfaces. Lancet 351: 1375-1376.
14. RAPPUOLI, R. et al. 1999. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today 20: 493-500.
15. GLUCK, R. et al. 2000. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J. Infect. Dis. 181: 1129-1132.
16. GLUECK, R. 2001. Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization. Vaccine 20(Suppl. 1): S42-44.
17. MUTSCH, M. et al. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350: 896-903.
18. FREYTAG, L.C. & J.D. CLEMENTS. 1999. Bacterial toxins as mucosal adjuvants. Curr. Top. Microbiol. Immunol. 236: 215-236.
19. HOLMGREN, J., C. CZERKINSKY, N. LYCKE & A. M. SVENNERHOLM. 1994. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier and adjuvant. Am. J. Trop. Med. Hyg. 50: 42-54.
20. VAN GINKEL, F.W. et al. 2003. Pneumococcal carriage results in ganglioside-mediated olfactory tissue infection. Proc. Natl. Acad. Sci. USA 100: 14363-14367.
21. VAN GINKEL, F.W. et al. 2000. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165: 4778-4782.
22. FUJIHASHI, K. et al. 2002. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20: 2431-2438.
23. DOUCE, G. et al. 1998. Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli. Vaccine 16: 1065-1073.
24. GIULIANI, M.M. et al. 1998. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 187: 1123-1132.
25. YAMAMOTO, S. et al. 1997. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J. Exp. Med. 185: 1203-1210.
26. SORIANI, M., L. BAILEY & T.R. HIRST. 2002. Contribution of the ADP-ribosylating and receptor-binding properties of cholera-like enterotoxins in modulating cytokine secretion by human intestinal epithelial cells. Microbiology 148: 667-676.
27. KAWAMURA, Y.I. et al. 2003. Cholera toxin activates dendritic cells through dependence on GM1-ganglioside which is mediated by NP-kappaB translocation. Eur. J. Immunol. 33: 3205-3212.
28. AGREN, L.C. et al. 1997. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol. 158: 3936-3946.
29. LYCKE, N. 2001. The B-cell targeted CTA1-DD vaccine adjuvant is highly effective at enhancing antibody as well as CTL responses. Curr. Opin. Mol. Ther. 3: 37-44.
30. LJUNGBERG, U.K. et al. 1993. The interaction between different domains of staphylococcal protein A and human polyclonal IgG, IgA, IgM and F(ab′)2: separation of affinity from specificity. Mol. Immunol. 30: 1279-1285.
31. UHLEN, M. et al. 1984. Complete sequence of the staphylococcal gene encoding protein A. A gene evolved through multiple duplications. J. Biol. Chem. 259: 1695-1702.
32. AGREN, L. et al. 2000. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects. J. Immunol. 164: 6276-6286.
33. AGREN, L.C. et al. 1999. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J. Immunol. 162: 2432-2440.
34. ERIKSSON, A.M., K.M. SCHON & N.Y. LYCKE. 2004. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J. Immunol. 173: 3310-3319.
35. HODGE, L.M. et al. 2001. Immunoglobulin A (IgA) responses and IgE-associated inflammation along the respiratory tract after mucosal but not systemic immunization. Infect. Immun. 69: 2328-2338.
36. LAVELLE, E.C. et al. 2004. Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent. J. Leukoc. Biol. 75: 756-763.
37. AGREN, L., B. LOWENADLER & N. LYCKE. 1998. A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit. Immunol. Cell Biol. 76: 280-287.
38. HAGIWAR, Y. et al. 2001. Effectiveness and safety of mutant Escherichia coli heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine. Vaccine 19: 2071-2079.
39. GIZURARSON, S. et al. 1992. Stimulation of the transepithelial flux of influenza HA vaccine by cholera toxin B subunit. Vaccine 10: 101-106.
40. LYCKE, N. et al. 1991. The adjuvant action of cholera toxin is associated with an increased intestinal permeability for luminal antigens. Scand. J. Immunol. 33: 691-698.
41. PALUCKA, K. & J. BANCHEREAU. 2002. How dendritic cells and microbes interact to elicit or subvert protective immune responses. Curr. Opin. Immunol. 14: 420-431.
42. GRANUCCI, F. & P. RICCIARDI-CASTAGNOLI. 2003. Interactions of bacterial pathogens with dendritic cells during invasion of mucosal surfaces. Curr. Opin. Microbiol. 6: 72-76.
43. SUNDQUIST, M., C. JOHANSSON & M.J. WICK. 2003. Dendritic cells as inducers of antimicrobial immunity in vivo. APMIS 111: 715-724.
44. KELSALL, B.L. & W. STROBER. 1996. Distinct populations of dendritic cells are present in the subepithelial dome and T cell regions of the murine Peyer's patch. J. Exp. Med. 183: 237-247.
45. SHREEDHAR, V.K., B.L. KELSALL & M.R. NEUTRA. 2003. Cholera toxin induces migration of dendritic cells from the subepithelial dome region to T- and B-cell areas of Peyer's patches. Infect. Immun. 71: 504-509.
46. RESCIGNO, M. et al. 2001. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. 2: 361-367.
47. STEINMAN, R.M. et al. 2000. The induction of tolerance by dendritic cells that have captured apoptotic cells [comment]. J. Exp. Med. 191: 411-416.
48. VINEY, J.L. et al. 1998. Expanding dendritic cells in vivo enhances the induction of oral tolerance. J. Immunol. 160: 5815-5825.
49. WILLIAMSON, E., G.M. WESTRICH & J.L. VINEY. 1999. Modulating dendritic cells to optimize mucosal immunization protocols. J. Immunol. 163: 3668-3675.
50. ITANO, A.A. et al. 2003. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 19: 47-57.
51. PULENDRAN, B. et al. 2001. Modulating the immune response with dendritic cells and their growth factors. Trends Immunol. 22: 41-47.
52. FINKELMAN, F.D. et al. 1996. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J. Immunol. 157: 1406-1414.
53. HAWIGER, D. et al. 2001. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194: 769-779.
54. LAVELLE, E.C. et al. 2003. Cholera toxin promotes the induction of regulatory T cells specific for bystander antigens by modulating dendritic cell activation. J. Immunol. 171: 2384-2392.
55. BROMANDER, A., J. HOLMGREN & N. LYCKE. 1991. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J. Immunol. 146: 2908-2914.
56. GAGLIARDI, M.C. et al. 2000. Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming. Eur. J. Immunol. 30: 2394-2403.
57. ERIKSSON, K. et al. 2003. Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development. Infect. Immun. 71: 1740-1747.
58. BRAUN, M.C. et al. 1999. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor beta1 and beta2 chain expression. J. Exp. Med. 189: 541-552.
59. VAJDY, M. et al. 1995. Impaired mucosal immune responses in interleukin 4-targeted mice. J. Exp. Med. 181: 41-53.
60. XU-AMANO, J. et al. 1993. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J. Exp. Med. 178: 1309-1320.
61. HORNQUIST, E. & N. LYCKE. 1993. Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur. J. Immunol. 23: 2136-2143.
62. SUN, J.B., J. HOLMGREN & C. CZERKINSKY. 1994. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc. Natl. Acad. Sci. USA 91: 10795-10799.
63. CZERKINSKY, C. et al. 1991. Detection of human cytokine-secreting cells in distinct anatomical compartments. Immunol. Rev. 119: 5-22.
64. AGREN, L. et al. 2000. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects. J. Immunol, 164: 6276-6286.
65. AGREN, L.C. et al. 1999. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig- binding activity. J. Immunol. 162: 2432-2440.
66. SIMMONS, C.P. et al. 1999. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. J. Immunol. 163: 6502-6510.
67. CHOI, A.H. et al. 2002. The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant. Vaccine 20: 1733-1740.
68. MOWAT, A.M. & J.L. VINEY. 1997. The anatomical basis of intestinal immunity. Immunol. Rev. 156: 145-166.
69. LYCKE, N. 1997. The mechanism of cholera toxin adjuvanticity. Res. Immunol. 148: 504-520.
70. JANG, M.H. et al. 2003. Induction of cytotoxic T lymphocyte responses by cholera toxin-treated bone marrow-derived dendritic cells. Vaccine 21: 1613-1619.
71. GRDIC, D. et al. 1999. The mucosal adjuvant effects of cholera toxin and immune-stimulating complexes differ in their requirement for IL-12, indicating different pathways of action. Eur. J. Immunol. 29: 1774-1784.
72. MOWAT, A.M. et al. 2001. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen. J. Immunol. 167: 3398-405.